Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 345.9% in March

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 4,190,000 shares, a growth of 345.9% from the February 28th total of 939,600 shares. Based on an average daily trading volume, of 22,260,000 shares, the short-interest ratio is presently 0.2 days. Currently, 17.7% of the company’s stock are sold short.

Institutional Investors Weigh In On Syros Pharmaceuticals

An institutional investor recently bought a new position in Syros Pharmaceuticals stock. Two Sigma Securities LLC purchased a new stake in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 107,742 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned 0.40% of Syros Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Stock Down 6.1 %

SYRS stock opened at $0.03 on Thursday. The firm has a market cap of $831,792.00, a PE ratio of -0.01 and a beta of 1.31. The business has a 50 day moving average of $0.15 and a 200-day moving average of $0.82. Syros Pharmaceuticals has a 12-month low of $0.03 and a 12-month high of $6.93.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of Syros Pharmaceuticals in a report on Friday, March 21st. They issued a “sell” rating on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.